BITEs: first-in-class bi-specific antibodies

Micromet’s BiTE (bi-specific T cell engager) antibody technology platform led to the creation of a clinical pipeline focused on new treatments for cancer and other conditions.

The lead product from the Micromet pipeline, BlincytoTM (Blinatumomab), was approved as a second-line treatment for relapsed or refractory acute lymphoblastic leukaemia.

CEO  Christian Itin

Advent Contact  Don Drakeman

Advent invested in 2001. Micromet listed on NASDAQ in 2006 (NASDAQ:MITI), and was acquired by Amgen for $1.16B in 2012.
Exited Investments
26 January 2012 in Micromet, Press Release

Amgen to Acquire Micromet

Press Release.   Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies Micromet's Proprietary BiTE® Platform has Potential to Improve Treatment in Multiple Tumor Types All-Cash Transaction…
Read More
15 June 2010 in Micromet, Press Release

Micromet’s Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin’s Lymphoma

Press Release.   Durable responses ranging up to 30 months observed   BETHESDA, Md., - Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1…
Read More
10 June 2009 in Micromet, Press Release

Micromet’s Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

Press Release.   German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Patients with Minimal Residual Disease  …
Read More